

1-((phosphonooxy)methyl)cyclopropyl, 1-(((dimethylglycyl)oxy)methyl)cyclopropyl,
trans-2-hydroxymethyl-cycloprop-1-yl, 1,2-dihydroxyethyl, 3-hydroxyoxetan-3-yl,
3-(hydroxy(C₁-C₃)alkyl)oxetan-3-yl, 3-aminooxetan-3-yl, 3-hydroxythietan-3-yl,
morpholin-4-yl(C₂-C₃)alkoxy, morpholin-4-yl-(C₁-C₂)alkyl, oxazol-2-yl or [1,2,3]triazol-

5 2-yl; and

R^{1B} represents hydroxy(C₁-C₃)alkyl, dihydroxy(C₂-C₄)alkyl, amino(C₁-C₃)alkyl,
(dimethylamino)methyl, 1-hydroxymethyl-cycloprop-1-yl,
trans-2-(1,2-dihydroxyethyl)cycloprop-1-yl, 1-methyl-2-hydroxymethyl-cycloprop-1-yl,
2-(hydroxymethyl)-2-methylcyclopropyl, 1-aminomethyl-cycloprop-1-yl,
10 *trans*-2-hydroxymethyl-cycloprop-1-yl, 1-fluoro-2-(hydroxymethyl)cyclopropyl, 2-fluoro-
2-(hydroxymethyl)cyclopropyl, 1-(hydroxymethyl)cyclobutyl, 3-hydroxyoxetan-3-yl,
3-hydroxymethyl-oxetan-3-yl, 3-hydroxythietan-3-yl, 1-(2-hydroxyacetyl)azetidin-3-yl,
1-(2-aminoacetyl)azetidin-3-yl, 1-glycylazetidin-3-yl, 1-(2-amino-
2-methylpropanoyl)azetidin-3-yl, 3-(2-aminoacetamido)cyclopentyl,
15 *trans*-(*cis*-3,4-dihydroxy)-cyclopent-1-yl, 3-hydroxymethylbicyclo[1,1,1]pentan-1-yl,
3-hydroxymethylbicyclo[1,1,1]pentan-1-yl, piperidin-4-yl, 1-(2-hydroxyacetyl)piperidin-
4-yl, 4-hydroxytetrahydro-2*H*-pyran-4-yl, 5-aminotetrahydro-2*H*-pyran-2-yl,
(1*s*,3*r*)-(1-hydroxy-3-(hydroxymethyl)cyclobutyl)methyl or 3-hydroxyoxetan-3-ylmethyl;

and to salts (in particular pharmaceutically acceptable salts) of compounds of formula I.

20 The present disclosure also provides, as a medicament, a compound of formula I as defined herein, or a pharmaceutically acceptable salt thereof.

The present disclosure also provides a pharmaceutical composition containing, as active principle, a compound of formula I as defined herein, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

25 The present disclosure further provides the use of a compound of formula I as defined herein, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention or treatment of a bacterial infection.

The present disclosure further provides the use of a compound or pharmaceutically acceptable salt as defined herein, for the manufacture of a medicament for the prevention
30 or treatment of a Gram-negative bacterial infection.

The following paragraphs provide definitions of the various chemical moieties for the compounds according to the invention and are intended to apply uniformly throughout the specification and claims, unless an otherwise expressly set out definition provides a broader or narrower definition:

- 5 ❖ The term “alkyl”, used alone or in combination, refers to a straight or branched chain alkyl group containing from one to four carbon atoms. The term “(C_x-C_y)alkyl” (x and y each being an integer) refers to a straight or branched chain alkyl group containing x to y carbon atoms. For example, a (C₁-C₃)alkyl group contains from one to three carbon atoms. Representative examples of alkyl groups include methyl, ethyl, propyl,
10 *iso*-propyl, *n*-butyl, *iso*-butyl, *sec*-butyl and *tert*-butyl. Preferred are methyl and ethyl. Most preferred is methyl.
- ❖ The term “hydroxyalkyl”, used alone or in combination, refers to an alkyl group as defined before wherein one hydrogen atom has been replaced by a hydroxy group. The

12. As a medicament, a compound of formula I as defined in one of claims 1 to 11, or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition containing, as active principle, a compound of formula I as defined in one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

14. Use of Aa compound of formula I as defined in one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in the prevention or treatment of a bacterial infection.

15. Use of Aa compound or pharmaceutically acceptable salt according to claim 14, for the manufacture of a medicament ~~which is for use in~~ the prevention or treatment of a Gram-negative bacterial infection.